Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mercadolibre Inc (MELI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Mercadolibre IncTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Mercadolibre Inc vs Zimmer Biomet Holdings Inc — how do they compare? Mercadolibre Inc trades at $1,847.93 (market cap $98.35B), while Zimmer Biomet Holdings Inc trades at $96.63 (market cap $18.55B). The key difference: Mercadolibre Inc is far larger — about 5.3× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.

MELIZBH
Market Cap
$98.35B$18.55B
Sector
Consumer CyclicalHealth
52-Week High
$2.51K$107.71
52-Week Low
$1.55K$79.58
Enterprise Value
$106.00B$25.61B
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mercadolibre Inc

MercadoLibre (MELI) trades at $1,876, up 2.83% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 EPS of $9.19, beating estimates, while revenue grew 50% year-over-year to exceed $10 billion for the first time. Analyst consensus remains strongly bullish with 23 buy ratings and a $2,150 price target, though margin compression from strategic investments has tempered near-term profit growth.

MELI's growth-first strategy is driving market share gains but pressuring margins, creating a tension between rapid expansion and profitability. The stock offers significant upside to analyst targets but faces execution risks from increased competition and macroeconomic volatility in Latin America. Long-term investors may find value in the ecosystem growth, while short-term volatility could persist amid margin concerns.

Zimmer Biomet Holdings Inc

ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.

The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mercadolibre Inc

MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.

Read more on MELI

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH